Journal
CALCIFIED TISSUE INTERNATIONAL
Volume 95, Issue 1, Pages 94-96Publisher
SPRINGER
DOI: 10.1007/s00223-014-9858-3
Keywords
Denosumab; Osteonecrosis; Teriparatide; Treatment
Categories
Funding
- Servier
- Novartis
- Negma
- Lilly
- Wyeth
- Amgen
- GlaxoSmithKline
- Roche
- Merckle
- Nycomed-Takeda
- NPS
- IBSA-Genevrier
- Theramex
- UCB
- Asahi Kasei
- Endocyte
- Merck Sharp and Dohme
- Rottapharm
- IBSA
- Genevrier
- Teijin
- Teva
- Analis
- Nycomed
- NovoNordisk
- Ebewee Pharma
- Zodiac
- Danone
- Will Pharma
- Bristol Myers Squibb
- Merck Sharp Dohme
- Organon
- Therabel
- Boehringer
- Chiltern
- Galapagos
Ask authors/readers for more resources
We report the first case of teriparatide adjuvant role in the management of a denosumab-induced osteonecrosis of the jaw in a male subject with idiopathic osteoporosis. Clinical benefits and CT healing were obtained within 2 months of teriparatide initiation and denosumab withdrawal. Increase in bone turnover previously described, when denosumab treatment is removed, might have a synergistic effect to the stimulating effect of teriparatide on bone remodeling to promptly heal osteonecrosis of the jaw.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available